An interventional study of RF Microneedle and Combination cream in Pigmentation and Pigmentation Disorder, sponsored by Ajou University School of Medicine. Completed at 1 site in Korea, Republic of. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-02-02.
Sponsored by Ajou University School of Medicine · Not applicable, Interventional, and Treatment
Melasma relapse is almost common after discontinuation of conventional treatment. Recent studies have suggested that photoaging dermis is main pathomechanism of melasma emphasizing stromal targeting therapy. Therefore, we investigated maintenance effect of microneedle radiofrequency (RF) for melasma treatment.
44 studies on the registry are indexed under Pigmentation Disorders; 11 are open to participants now.
This study's enrollment of 15 is below the median of 32 across 33 interventional studies indexed under Pigmentation Disorders.
Browse Pigmentation Disorders studies →Ajou University School of Medicine is the lead sponsor of 171 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Half face Oral tranexamic acid combined with triple combination cream with RF microneedle
Device: RF Microneedle · Drug: Combination cream
Half face Oral tranexamic acid combined with triple combination cream
Drug: Combination cream
Pulsed-type RF device in bipolar mode with 25 non-insulated microneedles every 2 weeks for 6 month
5% hydroquinone, 0.003% tretinoin, and 1% hydrocortisone twice daily for 2 months
Change of modified melasma area severity index score
Change of modified melasma area severity index score
Time frame: Every 1 month up to 8 months
Change of lightness value
Change of lightness value by a chromometer
Time frame: Every 1 month up to 8 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ajou University School of Medicine